FEMASYS INC (FEMY): Price and Financial Metrics Recent IPO


FEMASYS INC (FEMY): $6.52

-0.25 (-3.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FEMY Stock Price Chart Interactive Chart >

Price chart for FEMY

FEMY Price/Volume Stats

Current price $6.52 52-week high $13.75
Prev. close $6.77 52-week low $6.50
Day low $6.50 Volume 45,500
Day high $6.99 Avg. volume 144,886
50-day MA $7.32 Dividend yield N/A
200-day MA $0.00 Market Cap 76.94M

FEMASYS INC (FEMY) Company Bio


Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.


FEMY Latest News Stream


Event/Time News Detail
Loading, please wait...

FEMY Latest Social Stream


Loading social stream, please wait...

View Full FEMY Social Stream

Latest FEMY News From Around the Web

Below are the latest news stories about Femasys Inc that investors may wish to consider to help them evaluate FEMY as an investment opportunity.

Femasys Inc. To Join the Russell Microcap® Index

ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap® Index today when the U.S. market opened. The Russell Microcap Index is widely used by investment managers and institutional investors for index funds and as benchmarks for ac

Yahoo | September 20, 2021

Bullish insiders bet US$2.6m on Femasys Inc. (NASDAQ:FEMY)

In the last year, multiple insiders have substantially increased their holdings of Femasys Inc. ( NASDAQ:FEMY ) stock...

Yahoo | September 18, 2021

Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer

-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women’s healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry exp

Yahoo | September 1, 2021

Femasys Inc. Announces Financial Results for the Second Quarter of 2021

Completed initial public offering (“IPO”) raising net proceeds of $31.6 million Appointed Anne Morrissey to the Board of Directors, an industry expert with decades of medical device experience Initiated 792-patient, pivotal LOCAL trial after receipt of investigational device exemption (IDE) submission approval for FemaSeed™ ATLANTA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women’s healthcare with min

Yahoo | August 11, 2021

Femasys Inc. Announces First Patient Treated in Pivotal Trial for FemaSeed

First in Class Insemination Treatment for Infertility LOCAL Pivotal Trial to Enroll Up to 792 Patients Across 20 U.S. Centers ATLANTA, July 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on transforming women's healthcare, today announced the initiation and first patient treated in a pivotal trial evaluating FemaSeed, a first in class, localized directional insemination product candidate for infertility. “For more than 20 years, current approaches to infer

Yahoo | July 20, 2021

Read More 'FEMY' Stories Here

FEMY Price Returns

1-mo -11.29%
3-mo -34.07%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6665 seconds.